BUSINESS

Ohara’s High-Need Pediatric Cancer Drug in Limbo 2 Years after Approval due to GMP Issue

February 15, 2019

- Only subscribers can save articles.
  
  Sign In
  
  Subscribe

The pediatric cancer treatment Erwinase (crisantaspase), which was developed by Ohara Pharmaceutical at the request of a health ministry panel, still remains unlisted and unlaunched in Japan despite being approved in December 2016. Just after Erwinase was approved, a GMP…

To read the full story

Ohara’s Cancer Med Erwinase Reaches Japan Market Over 6 Years after Approval
June 15, 2023
Chuikyo OKs Listing of Mounjaro, Libtayo, Imjudo; 30 Billion-Plus Peak Sales for Lilly Med
March 9, 2023

BUSINESS

Eisai to Raise 50 Billion Yen via Bond Issue for R&D, Licensing
June 5, 2026
Japan Market for Fertility, Contraception, Female Disorders Put at 228.5 Billion Yen by FY2035
June 5, 2026
Toho, DHL Partner on Healthcare Logistics Platform
June 5, 2026
Keytruda Maintains Lead as Japan’s Top-Selling Drug for 32nd Month: Encise
June 5, 2026
Boehringer’s Japan Pharma Sales Up for 7th Straight Year, 10-Plus Launches Eyed by 2030
June 4, 2026

Chuikyo Debate on FY2026 Drug Pricing Reform

Chuikyo OKs New CEA Handling, with Third-Party Verification Ahead

Japan’s cost-effectiveness assessment (CEA) panel has approved a revised handling policy for the CEA system for FY2026, with the health…

COMMENTARY

Are Technical Discussions Enough for Japan’s CEA System?

By Ken Yoshino

Japan is finally launching technical discussions on its cost-effectiveness assessment (CEA) system. A health ministry-funded research group is set to…

COLUMN

The Patient North Star: How Gilead Japan Redefined Innovation

By Philip Carrigan

In the complex landscape of the Japanese pharmaceutical market, the “status quo” is often the safest harbor. But for leaders like Kennet Brysting, former president of Gilead Japan, the status quo is the most dangerous place to stay.Innovation in Japan…